Inhibition of Akt signaling in hepatoma cells induces apoptotic cell death independent of Akt activation status

Investigational New Drugs

Volumn 29, Issue 6, 2011, Pages 1303-1313

  Buontempo, Francesca ^a   Ersahin, Tulin ^b   Missiroli, Silvia ^a   Senturk, Serif ^b   Etro, Daniela ^a   Ozturk, Mehmet ^b   Capitani, Silvano ^a   Cetin Atalay, Rengul ^b   Neri, Maria Luca ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b BILKENT UNIVERSITY   (Turkey)

Author keywords

Akt; HCC; Inhibitor VIII; LY294002; PI3K; PTEN; RTCES; Wortmannin

Indexed keywords

PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN BAD; PROTEIN KINASE B; 1,3 DIHYDRO 1 (1 ((4 (6 PHENYL 1H IMIDAZO(4,5 G)QUINOXALIN 7 YL)PHENYL)METHYL) 4 PIPERIDINYL) 2H BENZIMIDAZOL 2 ONE; 1,3-DIHYDRO-1-(1-((4-(6-PHENYL-1H-IMIDAZO(4,5-G)QUINOXALIN-7-YL)PHENYL)METHYL)-4-PIPERIDINYL)-2H-BENZIMIDAZOL-2-ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC AGENT; BENZIMIDAZOLE DERIVATIVE; CHROMONE DERIVATIVE; MORPHOLINE DERIVATIVE; QUINOXALINE DERIVATIVE; WORTMANNIN;

APOPTOSIS; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG TARGETING; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HEPATOMA CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; DRUG ANTAGONISM; DRUG EFFECT; IC 50; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; TUMOR CELL LINE;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZIMIDAZOLES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHROMONES; HUMANS; INHIBITORY CONCENTRATION 50; LIVER NEOPLASMS; MORPHOLINES; PROTO-ONCOGENE PROTEINS C-AKT; QUINOXALINES; SIGNAL TRANSDUCTION;

EID: 84856032160     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9486-3     Document Type: Article

References (40)

1. McGlynn KA, Tsao L, Hsing AW, Devesa SS, Fraumeni JF Jr (2001) International trends and patterns of primary liver cancer. Int J Cancer 94:290-296. doi:10.1002/ijc.1456 (Pubitemid 32911426)
2. Ozturk N, Erdal E, Mumcuoglu M, Akcali KC, Yalcin O, Senturk S, Arslan-Ergul A, Gur B, Yulug I, Cetin-Atalay R, Yakicier C, Yagci T, Tez M, Ozturk M (2006) Reprogramming of replicative senescence in hepatocellular carcinoma-derived cells. Proc Natl Acad Sci USA 103:2178-2183. doi:10.1073/pnas.0510877103 (Pubitemid 43271643)
3. Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9:667-676. doi:10.1023/B:APPT.0000045801. 15585.dd (Pubitemid 40941196)
4. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390. doi:10.1056/NEJMoa0708857
5. Engelman JA (2009) Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer 9:550-562. doi:10.1038/nrc2664
6. Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644. doi:10.1038/nrd2926
7. Tokunaga E, Oki E, Egashira A, Sadanaga N, Morita M, Kakeji Y, Maehara Y (2008) Deregulation of the Akt pathway in human cancer. Curr Cancer Drug Targets 8:27-36 (Pubitemid 351237907)
8. Carnero A, Blanco-Aparicio C, Renner O, Link W, Leal JF (2008) The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets 8:187-198 (Pubitemid 351688437)
9. Hanada M, Feng J, Hemmings BA (2004) Structure, regulation and function of PKB/AKT-a major therapeutic target. Biochim Biophys Acta 1697:3-16. doi:10.1016/j.bbapap. 2003.11.009 (Pubitemid 38326757)
10. Salvesen HB, Stefansson I, Kretzschmar EI, Gruber P, MacDonald ND, Ryan A, Jacobs IJ, Akslen LA, Das S (2004) Significance of PTEN alterations in endometrial carcinoma: a population-based study of mutations, promoter methylation and PTEN protein expression. Int J Oncol 25:1615-1623
11. Xu G, Zhang W, Bertram P, Zheng XF, McLeod H (2004) Pharmacogenomic profiling of the PI3K/PTEN-AKT-mTOR pathway in common human tumors. Int J Oncol 24:893-900
12. Arcaro A, Guerreiro AS (2007) The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics 8:271-306. doi:10.2174/138920 207782446160 (Pubitemid 351210980)
13. Ozturk MEE, Ozturk N, Cetin-Atalay R and Irmak B (2005) Molecular Biology of Liver Cancer. In: RA M. Encyclopedia of Molecular Cell Biology and Molecular Medicine, Wiley-VCH, 2ed, vol. 7:323-335
14. Missiroli S, Etro D, Buontempo F, Ye K, Capitani S, Neri LM (2009) Nuclear translocation of active AKT is required for erythroid differentiation in erythropoietin treated K562 erythroleukemia cells. Int J Biochem Cell Biol 41(3):570-577
15. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A et al (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766
16. Kirstein SL, Atienza JM, Xi B, Zhu J, Yu N, Wang X, Xu X, Abassi YA (2006) Live cell quality control and utility of real-time cell electronic sensing for assay development. Assay Drug Dev Technol 4(5):545-553 (Pubitemid 46017398)
17. LoPiccolo J, Granville CA, Gills JJ, Dennis PA (2007) Targeting Akt in cancer therapy. Anticancer Drugs 18(8):861-874, Review (Pubitemid 47220704)
18. Sayan B, Tolga Emre NC, Irmak MB, Ozturk M, Cetin-Atalay R (2009) Nuclear exclusion of p33ING1b tumor suppressor protein: explored in HCC cells using a new highly specific antibody. Hybridoma 28:1-6. doi:10.1089/hyb.2008.0058
19. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G (1997) Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 278:687-689 (Pubitemid 27464966)
20. Barnett SF, Defeo-Jones D, Fu S, Hancock PJ, Haskell KM et al (2005) Identification and characterization of pleckstrin-homologydomaindependent and isoenzyme-specific Akt inhibitors. Biochem J 385:399-408. doi:10.1042/BJ20041140 (Pubitemid 40165072)
21. Zhao Z, Leister WH, Robinson RG, Barnett SF, Defeo-Jones D, Jones RE, Hartman GD, Huff JR, Huber HE, Duggan ME, Lindsley CW (2005) Discovery of 2, 3, 5-trisubstituted pyridine derivatives as potent Akt1 and Akt2 dual inhibitors. Bioorg Med Chem Lett 15:905-909. doi:10.1016/j.bmcl.2004.12.062 (Pubitemid 40458621)
22. Manning BD, Cantley LC (2007) AKT/PKB signaling: navigating downstream. Cell 129:1261-1274. doi:10.1016/j.cell.2007.06.009 (Pubitemid 46962095)
23. Fabregat I (2009) Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 15:513-520
24. Kim MJ, Oh SJ, Park SH, Kang HJ, Won MH, Kang TC, Hwang IK, Park JB, Kim JI, Kim J, Lee JY (2007) Hypoxia-induced cell death of HepG2 cells involves a necrotic cell death mediated by calpain. Apoptosis 12:707-718. doi:10.1007/s10495-006-0002-3 (Pubitemid 46411470)
25. Messam CA, Pittman RN (1998) Asynchrony and commitment to die during apoptosis. Exp Cell Res 238:389-398. doi:10.1006/excr.1997.3845 (Pubitemid 28372826)
26. Gobeil S, Boucher CC, Nadeau D, Poirier GG (2001) Characterization of the necrotic cleavage of poly (ADP-ribose) polymerase (PARP-1): implication of lysosomal proteases. Cell Death Differ 8:588-594. doi:10.1038/sj.cdd.4400851 (Pubitemid 32586595)
27. Blommaart EF, Krause U, Schellens JP, Vreeling-Sindelarova H, Meijer AJ (1997) The phosphatidylinositol 3-kinase inhibitors wortmannin and LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem 243:240-246 (Pubitemid 27060408)
28. Cully M, You H, Levine AJ, Mak TW (2006) Beyond PTEN mutations: the PI3K pathway as an integrator of multiple inputs during tumorigenesis. Nat Rev Cancer 6(3):184-192, Review (Pubitemid 43292562)
29. Schmitz KJ, Wohlschlaeger J, Lang H, Sotiropoulos GC, Malago M et al (2008) Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 48:83-90. doi:10.1016/j.jhep. 2007.08.018 (Pubitemid 350191996)
30. Nakanishi K, Sakamoto M, Yamasaki S, Todo S, Hirohashi S (2005) Akt phosphorylation is a risk factor for early disease recurrence and poor prognosis in hepatocellular carcinoma. Cancer 103(2):307-312 (Pubitemid 40129290)
31. Hu TH, Huang CC, Lin PR, Chang HW, Ger LP, Lin YW, Changchien CS, Lee CM, Tai MH (2003) Expression and prognostic role of tumor suppressor gene PTEN/MMAC1/TEP1 in hepatocellular carcinoma. Cancer 97(8):1929-1940
32. Boyault S, Rickman DS, de Reynies A, Balabaud C, Rebouissou S, Jeannot E, Herault A, Saric J, Belghiti J, Franco D (2007) (2008) Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 45:42-52 (Pubitemid 46144363)
33. Recher C, Dos Santos C, Demur C, Payrastre B (2005) mTOR, a new therapeutic target in acute myeloid leukemia. Cell Cycle 4:1540-1549
34. Lindsley CW, Barnett SF, Layton ME, Bilodeau MT (2008) The PI3K/Akt pathway: recent progress in the development of ATPcompetitive and allosteric Akt kinase inhibitors. Curr Cancer Drug Targets 8:7-18 (Pubitemid 351237905)
35. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, Klevernic I, Arthur JS, Alessi DR, Cohen P (2007) The selectivity of protein kinase inhibitors: a further update. Biochem J 408:297-315. doi:10.1042/BJ20070797
36. Beurel E, Kornprobst M, Blivet-Van Eggelpoel MJ, Cadoret A, Capeau J, Desbois-Mouthon C (2005) GSK-3beta reactivation with LY294002 sensitizes hepatoma cells to chemotherapyinduced apoptosis. Int J Oncol 27:215-222
37. Erdal E, Ozturk N, Cagatay T, Eksioglu-Demiralp E, Ozturk M (2005) Lithium-mediated downregulation of PKB/Akt and cyclin E with growth inhibition in hepatocellular carcinoma cells. Int J Cancer 115:903-910. doi:10.1002/ijc.20972 (Pubitemid 40791830)
38. Ballou LM, Selinger ES, Choi JY, Drueckhammer DG, Lin RZ (2007) Inhibition of mammalian target of rapamycin signaling by 2-(morpholin-1-yl) pyrimido[2, 1-alpha]isoquinolin-4-one. J Biol Chem 282:24463-24470. doi:10.1074/jbc. M704741200 (Pubitemid 47328068)
39. Okamoto T, Sanda T, Asamitsu K (2007) NF-kappa B signaling and carcinogenesis. Curr Pharm Des 13:447-462
40. Irmak MB, Ince G, Ozturk M, Cetin-Atalay R (2003) Acquired tolerance of hepatocellular carcinoma cells to selenium deficiency: a selective survival mechanism? Cancer Res 63:6707-6715 (Pubitemid 37322950)